Browse

Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients

Cited 14 time in Web of Science Cited 17 time in Scopus
Authors
Park, Y. H.; Lee, J. J.; Ryu, M. H.; Kim, S. Y.; Kim, D. H.; Do, Y. R.; Lee, K. H.; Oh, S. J.; Kim, Y. K.; Suh, C. W.; Heo, D. S.; RYoo, B. Y.; Kim, J. K.; Song, H. S.; Lee, W. S.; Kim, H. J.; Bang, Yung-Jue; Yang, S. H.; Sohn, S. K.; Kang, Y. K.
Issue Date
2006-04
Publisher
Springer Verlag
Citation
Annals of Hematology, Vol.85 No.4, pp.257-262
Keywords
rituximabCHOPDLBCL
Abstract
The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been shown to improve the outcome in all age groups with newly diagnosed diffuse large B-cell lymphoma (DLBCL). We conducted a retrospective analysis to evaluate the impact of this combination therapy on DLBCL outcomes in Korea. From October 2001 to June 2004, newly diagnosed DLBCL patients in nine Korean institutes were included. All of these 81 patients were treated with three or more cycles of rituximab plus CHOP (R-CHOP) combination chemotherapy (R group), and followed for a minimum of 12 months. For comparison, a historical cohort of patients was used and analyzed for "Clinicopathologic characteristics of Korean non-Hodgkin's lymphomas (NHLs) based on Revised American Lymphoma (REAL) classification" in 1999. Among the 1,098 NHL patients, the data of 214 DLBCL patients, who were treated with CHOP chemotherapy in first-line, were analyzed (C group). We compared outcomes between the C group and the R group. A total of 295 patients were evaluated (C group, 214; R group, 81). The complete response (CR) rate was higher in R group (73 vs 91%, p=0.001). The 2-year event-free survival (EFS) rate was significantly higher in R group (78 vs 85%, p=0.0194). This survival benefit was maintained in high-risk patients according to the international prognostic index (IPI) (p=0.0039), regardless of age. However, there was no significant difference in low-risk patients. The addition of rituximab to CHOP combination chemotherapy for DLBCLs showed improved outcomes, particularly in high-risk group according to the IPI. Long-term follow-up results will be needed to confirm these results.
ISSN
0939-5555
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16416337

https://hdl.handle.net/10371/47162
DOI
https://doi.org/10.1007/s00277-005-0060-6
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse